Lipid-based Nanoparticles for the Targeted Delivery of Anticancer Drugs: A Review

Author:

Moghaddam Mehrdad Moosazadeh1ORCID,Khodaverdi Hamed2,Zeini Maryam Shokrian34,Vazifedust Soheil5,Akbariqomi Mostafa6,Tebyaniyan Hamid7

Affiliation:

1. Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

2. National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran

3. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

4. Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran

5. Faculty of Veterinary Medicine, University of Urmia, Urmia, Iran

6. Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

7. Islamic Azad University, Science and Research Branch, Tehran, Iran

Abstract

Abstract: Cancer is one of the leading causes of mortality worldwide. Although chemotherapeutic agents have been effectively designed to increase the survival rates of some patients, the designed chemotherapeutic agents necessarily deliver toxic chemotherapeutic drugs to healthy tissues, resulting in serious side effects. Cancer cells can often acquire drug resistance after repeatedly administering current chemotherapeutic agents, restricting their efficacy. Given such obstacles, investigators have attempted to distribute chemotherapeutic agents using targeted drug delivery systems (DDSs), especially nanotechnology-based DDSs. The lipid-based nanoparticles (LBNPs) are a large and complex class of substances utilized to manage various diseases, especially cancers. Liposomes seem to be the most frequently employed LBNPs, owing to their high biocompatibility, bioactivity, stability, and flexibility. Solid lipid NPs and non-structured lipid carriers have lately received a lot of interest. In addition, several reports focused on novel therapies via LBNPs to manage various forms of cancer. In the present research, the latest improvements in applying LBNPs have been shown to deliver different therapeutic agents to cancerous cells and be a quite successful candidate in cancer therapy.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmaceutical Science

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3